Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
- Written by PR Newswire
- Chime Biologics to support the late-stage clinical study and to provide global commercial manufacturing services for Hope Medicine's first-in-class monoclonal antibody drug, HMI-115.
- The first-in-class mAb will benefit endometriosis and androgenetic alopecia patients.
SHANGHAI, Oct. 26, 2023 /PRNewswire/ -- Chime Biologics, a...














